PETALING JAYA, Malaysia, April 30, 2025 /PRNewswire/ -- CARiNG Pharmacy has officially launched its Bye Bye Sensitive Skin section across all its outlets nationwide — a move that reinforces the brand's commitment to helping Malaysians manage sensitive and eczema-prone skin with confidence and care.
The launch event, held at 1 Utama Shopping Centre brought together healthcare professionals, skincare experts, and members of the public for a day filled with educational talks, panel discussions, and live demonstrations — all focused on better skin health.
Speaking at the event, Mr. Chong Yeow Siang, Managing Director of CARiNG Pharmacy, shared the inspiration behind this initiative:
"We know that sensitive and eczema-prone skin can have a big impact on daily life. Through this initiative, we want to be more than just a place to buy products — we want to be a reliable support system. With trusted skincare options and well-trained pharmacists in every outlet, we're here to walk the journey with our customers."
The Bye Bye Sensitive Skin section features over 50 skincare brands known for their gentle, dermatologically tested, and fragrance-free formulations — carefully selected to suit conditions such as eczema, rosacea, psoriasis, and other sensitivity-related concerns.
As part of the initiative, more than 300 CARiNG pharmacists across Malaysia have been certified as Atopic Eczema Counsellors. This ensures that customers receive professional advice and personalised recommendations, whether they're shopping for their children, elderly family members, or themselves.
The launch event included a panel discussion featuring the President of the Malaysian Eczema Association, who highlighted the rising awareness of eczema in Malaysia and the need for early intervention and education. Joining the panel was Dr. Amanda Elli, a respected dermatologist and skincare expert, who shared insights on identifying triggers, choosing suitable products, and maintaining a healthy skin routine.
In her talk, Dr. Amanda stressed the importance of public awareness and accessible care:
"It's great to see a retail pharmacy taking such a proactive role in sensitive skin care. Many Malaysians live with eczema or skin sensitivity without knowing where to turn. Initiatives like this can make a real difference."
Dr. Amanda also conducted a live demonstration on how to properly cleanse sensitive skin — an essential yet often misunderstood step in any skincare routine. The crowd learned simple but effective techniques to protect the skin barrier and prevent flare-ups, especially for children and those with chronic skin issues.
Members of the public are invited to visit the ongoing Bye Bye Sensitive Skin roadshow at 1 Utama Shopping Centre, Ground Floor Centre Court, which runs from 29 April to 4 May 2025. Visitors can enjoy complimentary skin consultations, product sampling, exclusive deals, and guidance from trained CARiNG pharmacists throughout the week.
Whether you're new to managing skin sensitivity or have been living with it for years, the Bye Bye Sensitive Skin section is designed to provide a safe, trusted space where customers can find effective solutions and real support.
CARiNG Pharmacy welcomes everyone to experience the new section at any outlet nationwide — and to discover how the right care can make all the difference.
About CARiNG Pharmacy Group
CARiNG Pharmacy is a homegrown Malaysian pharmacy that has been a trusted name among Malaysians since 1994. In 2021, they acquired Georgetown Pharmacy and Wellings Pharmacy that serves the Northern Region of Malaysia, forming CARiNG Pharmacy Group. CARiNG Pharmacy Group has been committed to enhancing the health and well-being of our community. They have grown to a total of over 250 stores nationwide, introduced innovative health services, and embraced green practices, all in line with the vision to be the most trusted and admired pharmacy in Malaysia.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CARiNG Pharmacy Launches "Bye Bye Sensitive Skin" Nationwide -- Reinforces Position as a Leader in Sensitive Skin Solutions
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
